Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Intravenous iron (Monofer) for iron deficiency in severe aortic stenosis undergoing TAVI
2019-002037-11Phase 2Completed
- Sponsor
- Oslo University Hospital
- Start
- Aug 2019
- Modality
- Small Molecules, Biodegradable Polymers → Polymer-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 2 trial of ferric derisomaltose in iron deficiency anemia (IDA) and aortic stenosis (AS), sponsored by Oslo University Hospital. Primary endpoint: 6-minute walk distance at 6 months. Started Aug 2019; status: completed.
02
Drugs
ferric derisomaltose
03
Conditions
iron deficiency anemia (IDA)aortic stenosis (AS)
Beyond the preview
Go deeper on 2019-002037-11.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2019-002037-11.